Regeneron and Sanofi expand antibody partnership with $1 billion upfront payment and up to $7 billion in milestones
On October 1 2026 Regeneron and Sanofi signed a Sixth Amendment to their antibody license agreement, adding four new long‑acting antibodies targeting IL‑13, IL‑4, IL‑4Rα and a bispecific IL‑4×IL‑13. Sanofi will provide Regeneron an upfront cash payment of $1.0 billion and may pay as much as $7.0 billion in future milestone fees. Regeneron will continue to lead U.S. development and regulatory work while Sanofi will handle worldwide commercialization, and the companies settled a related lawsuit over Dupixent data access.
Why it matters
The cash infusion and potential milestone earnings increase Regeneron’s near‑term liquidity and could boost its earnings if milestones are achieved, as noted by TipRanks analysts. The expanded pipeline may also enhance Sanofi’s future product portfolio and revenue streams.
Key facts
- 1The amendment was signed on October 1 2026. tradingview.com
- 2Four new antibodies targeting IL‑13, IL‑4, IL‑4Rα and a bispecific IL‑4×IL‑13 were added to the collaboration. tradingview.com
- 3Sanofi will provide an upfront cash payment of $1.0 billion to Regeneron. tradingview.com
- 4Regeneron may receive up to $7.0 billion in milestone payments under the expanded deal. tradingview.com
- 5Regeneron retains lead development and U.S. regulatory responsibilities; Sanofi leads global commercialization. tradingview.com
- 6The companies settled a lawsuit concerning access to Dupixent commercialization data. tradingview.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.